Hall KJ, Jones ML, Poole AW (2007) Coincident regulation of PKCdelta in human platelets by phosphorylation of Tyr311 and Tyr565 and phospholipase C signalling. Biochem J 406, 501-9 17570831

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y52-p - PKCD (human) ▲

Modsite: VQKKPtMyPEWKSTF SwissProt Entrez-Gene Orthologous residues PKCD (human): Y52‑p, PKCD iso2 (human): Y52‑p, PKCD (mouse): Y52‑p, PKCD iso2 (mouse): Y52‑p, PKCD (rat): Y52‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  platelet-blood Cellular systems studied:  primary cells Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes vanadate increase collagen no change compared to control thrombin no change compared to control PAR1-activating_peptide no change compared to control PAR4-activating_peptide no change compared to control

Y155-p - PKCD (human) ▲

Modsite: IKQAKIHyIKNHEFI SwissProt Entrez-Gene Orthologous residues PKCD (human): Y155‑p, PKCD iso2 (human): Y155‑p, PKCD (mouse): Y155‑p, PKCD iso2 (mouse): Y155‑p, PKCD (rat): Y155‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  platelet-blood Cellular systems studied:  primary cells Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes vanadate increase collagen no change compared to control thrombin no change compared to control PAR1-activating_peptide no change compared to control PAR4-activating_peptide no change compared to control

Y313-p - PKCD (human) ▲

Modsite: ssEPVGIyQGFEKkT SwissProt Entrez-Gene Orthologous residues PKCD (human): Y313‑p, PKCD iso2 (human): Y313‑p, PKCD (mouse): Y311‑p, PKCD iso2 (mouse): Y311‑p, PKCD (rat): Y311‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  platelet-blood Cellular systems studied:  primary cells Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme PHOSPHATASE PTP1B (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase PP1 thrombin inhibit treatment-induced increase PP2 thrombin inhibit treatment-induced increase PP3 thrombin no effect upon treatment-induced increase U73122 thrombin inhibit treatment-induced increase piceatannol thrombin no effect upon treatment-induced increase LFM-A13 thrombin no effect upon treatment-induced increase collagen increase PAR1-activating_peptide increase PAR4-activating_peptide increase phorbol_ester increase PP1 phorbol_ester inhibit treatment-induced increase PP2 phorbol_ester inhibit treatment-induced increase PP3 phorbol_ester no effect upon treatment-induced increase U73122 phorbol_ester no effect upon treatment-induced increase piceatannol phorbol_ester no effect upon treatment-induced increase LFM-A13 phorbol_ester no effect upon treatment-induced increase

Y334-p - PKCD (human) ▲

Modsite: MQDNsGtyGkIWEGs SwissProt Entrez-Gene Orthologous residues PKCD (human): Y334‑p, PKCD iso2 (human): Y365‑p, PKCD (mouse): Y332‑p, PKCD iso2 (mouse): Y358‑p, PKCD (rat): Y332‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  platelet-blood Cellular systems studied:  primary cells Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes vanadate increase collagen no change compared to control thrombin no change compared to control PAR1-activating_peptide no change compared to control PAR4-activating_peptide no change compared to control

T507-p - PKCD (human) ▲

Modsite: FGEsRAstFCGtPDy SwissProt Entrez-Gene Orthologous residues PKCD (human): T507‑p, PKCD iso2 (human): T538‑p, PKCD (mouse): T505‑p, PKCD iso2 (mouse): T531‑p, PKCD (rat): T505‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  platelet-blood Cellular systems studied:  primary cells Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase PP1 thrombin inhibit treatment-induced increase U73122 thrombin inhibit treatment-induced increase phorbol_ester increase

Y525-p - PKCD (human) ▲

Modsite: EILQGLKyTFSVDWW SwissProt Entrez-Gene Orthologous residues PKCD (human): Y525‑p, PKCD iso2 (human): Y556‑p, PKCD (mouse): Y523‑p, PKCD iso2 (mouse): Y549‑p, PKCD (rat): Y523‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  platelet-blood Cellular systems studied:  primary cells Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes vanadate increase collagen no change compared to control thrombin no change compared to control PAR1-activating_peptide no change compared to control PAR4-activating_peptide no change compared to control

Y567-p - PKCD (human) ▲

Modsite: IRVDTPHyPRWITKE SwissProt Entrez-Gene Orthologous residues PKCD (human): Y567‑p, PKCD iso2 (human): Y598‑p, PKCD (mouse): Y565‑p, PKCD iso2 (mouse): Y591‑p, PKCD (rat): Y565‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  platelet-blood Cellular systems studied:  primary cells Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme PHOSPHATASE PTP1B (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes thrombin increase PP1 thrombin inhibit treatment-induced increase PP2 thrombin inhibit treatment-induced increase PP3 thrombin no effect upon treatment-induced increase U73122 thrombin inhibit treatment-induced increase piceatannol thrombin no effect upon treatment-induced increase LFM-A13 thrombin no effect upon treatment-induced increase collagen increase PAR1-activating_peptide increase PAR4-activating_peptide increase phorbol_ester increase PP1 phorbol_ester inhibit treatment-induced increase PP2 phorbol_ester inhibit treatment-induced increase PP3 phorbol_ester no effect upon treatment-induced increase U73122 phorbol_ester no effect upon treatment-induced increase piceatannol phorbol_ester no effect upon treatment-induced increase LFM-A13 phorbol_ester no effect upon treatment-induced increase

Y419-p - Src (human) ▲

Modsite: RLIEDNEytARQGAk SwissProt Entrez-Gene Orthologous residues Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y418‑p, Src iso1 (mouse): Y424‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  platelet-blood Cellular systems studied:  primary cells Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes U73122 no change compared to control PP1 decrease thrombin increase U73122 thrombin inhibit treatment-induced increase PP1 thrombin inhibit treatment-induced increase phorbol_ester no change compared to control